Cargando…
A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart
Cardiac failure is a major cause of mortality and morbidity worldwide, since the standard treatment for cardiac failure in the clinical practice is chiefly to focus on removal of insults against the heart or minimisation of additional factors to exacerbate cardiac failure, but not on regeneration of...
Autores principales: | Fukushima, Satsuki, Miyagawa, Shigeru, Sakai, Yoshiki, Sawa, Yoshiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464640/ https://www.ncbi.nlm.nih.gov/pubmed/25708182 http://dx.doi.org/10.1007/s10741-015-9477-8 |
Ejemplares similares
-
Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis
por: Tada, Satoru, et al.
Publicado: (2019) -
Administration of Slow-Release Synthetic Prostacyclin Agonist Promoted Angiogenesis and Skeletal Muscle Regeneration for Limb Ischemia
por: Nakagawa, Takaya, et al.
Publicado: (2020) -
Enhanced Pulmonary Vascular and Alveolar Development via Prenatal Administration of a Slow-Release Synthetic Prostacyclin Agonist in Rat Fetal Lung Hypoplasia
por: Umeda, Satoshi, et al.
Publicado: (2016) -
Innovative therapeutic strategy using prostaglandin I(2) agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension
por: Kanaya, Tomomitsu, et al.
Publicado: (2021) -
Synthetic Prostacyclin Agonist Attenuates Pressure-Overloaded Cardiac Fibrosis by Inhibiting FMT
por: Masada, Kenta, et al.
Publicado: (2020)